Date: 2015-04-21
Type of information: Series B financing round
Company: Dimension Therapeutics (USA - MA)
Investors: New Leaf Venture Partners (USA - NY - CA) Jennison Associates Partner Fund Management (USA) RA Capital Management (USA - MA) Rock Springs Capital (USA - MD) Tourbillon Global Ventures (USA) Fidelity Biosciences (USA - MA) OrbiMed (USA - NY)
Amount: $65 Million
Funding type: series B financing round
Planned used: Dimension Therapeutics plans to use the proceeds from the financing to further advance the company’s adeno-associated virus (AAV) platform and growing pipeline of gene therapy programs. The company’s first program is expected to enter clinical testing in patients with hemophilia B in the second half of 2015. Additional programs to treat indications in rare diseases are anticipated to enter IND-enabling studies during the next 12 to 18 months, with the objective of advancing three clinic-ready programs next year.
Others: * On April 21, 2015, Dimension Therapeutics, a rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, announced the successful completion of a Series B financing totaling $65 million. New investor New Leaf Venture Partners led the financing, with participation from additional new investors Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, and Tourbillon Global Ventures, and another life sciences investor. Dimension’s existing investors Fidelity Biosciences and OrbiMed also participated in the round. In association with the financing, Mike Dybbs, Ph.D., Partner, New Leaf Venture Partners, has joined Dimension’s Board of Directors. The Company also announced that Allan M. Fox of FOXKISER, the founders of REGENXBIO, is leaving his position as a member of the Company’s Board of Directors.
Therapeutic area: Rare diseases - Genetic diseases
